Carranza LS, Guerrero ML, Castro A

Language: Spanish
References: 11
Page: 367-371
PDF size: 214.79 Kb.

ABSTRACT

Introduction: Metabolic syndrome is related with a significant increase in some chronic-degenerative diseases. In the same manner in the postmenopause exist several and metabolic changes.
Objective: To determine the frequency of metabolic syndrome in Mexican postmenopausal women that receive or not hormone therapy.
Material and methods: 33 postmenopausal women divided in two groups one without hormone therapy and the other received conjugated equine estrogens plus medroxyprogesterone acetate 0.625/2.5 mg/day. Age was documented; weight, height, waist and hip perimeters as well as blood pressure were analyzed. Body mass index and waist-hip ratio were calculated. Glucose and lipid levels were measured. Statistical analysis was done with Student’s test for independent samples for comparison among the groups.
Results: Thirty-three patients were studied, 17 were in the group without hormone therapy and 16 in the group with hormone therapy with conjugated equine estrogens and medroxyprogesterone acetate 0.625/2.5 mg/day were studied. When the groups were compared, the waist perimeter was significantly greater in the group without hormone therapy (98.7 ± 7.8 cm vs. 92.9 ± 9.1 cm, respectively, p ‹ 0.05). No significant differences were found between the groups in blood pressure, glucose, total cholesterol, high-density lipoprotein cholesterol and triglycerides. Metabolic syndrome diagnostic criteria were completed in 12 patients of group 1 (70.6%) and 8 in group 2 (50%), without statistically significant difference between them.
Conclusion: Hormone therapy group was associated to a lower abdominal perimeter and a lower waist-hip ratio. This let’s suppose that hormone therapy has a beneficial effect on the prevention of metabolic syndrome.

REFERENCES

1. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433-8.

2. Kip KE, Marroquin OC, Kelley DE, Johnson BD, et al. Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women: a report from the Women’s Ischemia Syndrome Evaluation (WISE) study. Circulation 2004;109:706-13.

3. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.

4. Mathur R. Metabolic syndrome. Dirección URL: .

5. Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 2003;88:2404-11.

6. Balkau B, Vernay M, Mhamdi L, Novak M, et al. The incidence and persistence of the NCEP (National Cholesterol Education Program) metabolic syndrome. The French D.E.S.I.R. study. Diabetes Metab 2003;29:526-32.

7. Ford ES, Giles WH, Dietz WH. Prevalence on the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;281:356-9.

8. Aguilar-Salinas CA, Rojas R, Gómez-Pérez FJ, Franco A, y col. El síndrome metabólico: concepto en evolución. Gac Med Mex 2004;140:541-8.

9. Carranza LS. Climaterio. En: Fundamentos de endocrinología ginecológica y reproductiva. México: Masson Doyma, 2003;pp:299-324.

10. Green JS, Stanforth PR, Rankinen T, Leon AS, et al. The effects of exercise training on abdominal visceral fat, body composition, and indicators of the metabolic syndrome in postmenopausal women with and without estrogen replacement therapy: the HERITAGE family study. Metabolism 2004;53:1192-6.

11. Laaksonen DE, Niskanen L, Lakka HM, Lakka TA, Uusitupa M. Epidemiology and treatment of the metabolic syndrome. Ann Med 2004;36:332-46.